Literature DB >> 26616873

Lipoic acid reduces inflammation in a mouse focal cortical experimental autoimmune encephalomyelitis model.

Priya Chaudhary1, Gail Marracci2, Danielle Galipeau3, Edvinas Pocius3, Brooke Morris3, Dennis Bourdette4.   

Abstract

Cortical lesions are a crucial part of MS pathology and it is critical to determine that new MS therapies have the ability to alter cortical inflammatory lesions given the differences between white and gray matter lesions. We tested lipoic acid (LA) in a mouse focal cortical EAE model. Brain sections were stained with antibodies against CD4, CD11b and galectin-3. Compared with vehicle, treatment with LA significantly decreased CD4+ and galectin-3+ immune cells in the brain. LA treated mice had fewer galectin-3+ cells with no projections indicating decrease in the number of infiltrating monocytes. LA significantly reduces inflammation in a focal cortical model of MS.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cortical lesions; Focal EAE; Immunofluorescence; Inflammation; Multiple sclerosis

Mesh:

Substances:

Year:  2015        PMID: 26616873      PMCID: PMC4664888          DOI: 10.1016/j.jneuroim.2015.10.011

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  19 in total

1.  Lipoic acid inhibits expression of ICAM-1 and VCAM-1 by CNS endothelial cells and T cell migration into the spinal cord in experimental autoimmune encephalomyelitis.

Authors:  Priya Chaudhary; Gail H Marracci; Dennis N Bourdette
Journal:  J Neuroimmunol       Date:  2006-04-27       Impact factor: 3.478

2.  Lipoic acid affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity.

Authors:  Gerty Schreibelt; René J P Musters; Arie Reijerkerk; Lody R de Groot; Susanne M A van der Pol; Esther M L Hendrikx; Ed D Döpp; Christine D Dijkstra; Benjamin Drukarch; Helga E de Vries
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

3.  Direct injection of cytokines into the spinal cord causes autoimmune encephalomyelitis-like inflammation.

Authors:  R D Simmons; D O Willenborg
Journal:  J Neurol Sci       Date:  1990-12       Impact factor: 3.181

4.  Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis.

Authors:  Gail H Marracci; Richard E Jones; Gabriel P McKeon; Dennis N Bourdette
Journal:  J Neuroimmunol       Date:  2002-10       Impact factor: 3.478

5.  A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination.

Authors:  Doron Merkler; Tristan Ernsting; Martin Kerschensteiner; Wolfgang Brück; Christine Stadelmann
Journal:  Brain       Date:  2006-05-19       Impact factor: 13.501

6.  Grey matter pathology in multiple sclerosis.

Authors:  Marco Vercellino; Federica Plano; Barbara Votta; Roberto Mutani; Maria Teresa Giordana; Paola Cavalla
Journal:  J Neuropathol Exp Neurol       Date:  2005-12       Impact factor: 3.685

7.  In vivo PET imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis.

Authors:  Laura Airas; Alex M Dickens; Petri Elo; Päivi Marjamäki; Jarkko Johansson; Olli Eskola; Paul A Jones; William Trigg; Olof Solin; Merja Haaparanta-Solin; Daniel C Anthony; Juha Rinne
Journal:  J Nucl Med       Date:  2015-01-08       Impact factor: 10.057

Review 8.  TNF-alpha- and IFN-gamma-mediated signal transduction pathways: effects on glial cell gene expression and function.

Authors:  E N Benveniste; D J Benos
Journal:  FASEB J       Date:  1995-12       Impact factor: 5.191

9.  Cytokine-induced enhancement of autoimmune inflammation in the brain and spinal cord: implications for multiple sclerosis.

Authors:  D Sun; T A Newman; V H Perry; R O Weller
Journal:  Neuropathol Appl Neurobiol       Date:  2004-08       Impact factor: 8.090

10.  Targeting experimental autoimmune encephalomyelitis lesions to a predetermined axonal tract system allows for refined behavioral testing in an animal model of multiple sclerosis.

Authors:  Martin Kerschensteiner; Christine Stadelmann; Bigna S Buddeberg; Doron Merkler; Florence M Bareyre; Daniel C Anthony; Christopher Linington; Wolfgang Brück; Martin E Schwab
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

View more
  16 in total

Review 1.  Crosstalk between metabolism and epigenetic modifications in autoimmune diseases: a comprehensive overview.

Authors:  Zijun Wang; Hai Long; Christopher Chang; Ming Zhao; Qianjin Lu
Journal:  Cell Mol Life Sci       Date:  2018-07-04       Impact factor: 9.261

2.  Lipoic Acid Stimulates cAMP Production in Healthy Control and Secondary Progressive MS Subjects.

Authors:  Sarah E Fiedler; Vijayshree Yadav; Amelia R Kerns; Catherine Tsang; Sheila Markwardt; Edward Kim; Rebecca Spain; Dennis Bourdette; Sonemany Salinthone
Journal:  Mol Neurobiol       Date:  2017-11-15       Impact factor: 5.590

3.  Protective Effects of Leukadherin1 in a Rat Model of Targeted Experimental Autoimmune Encephalomyelitis (EAE): Possible Role of P47phox and MDA Downregulation.

Authors:  Sara Hemmati; Mohammad Amin Sadeghi; Hasan Yousefi-Manesh; Mostafa Eslamiyeh; Ali Vafaei; Laleh Foroutani; Ghazaleh Donyadideh; AhmadReza Dehpour; Nima Rezaei
Journal:  J Inflamm Res       Date:  2020-07-31

Review 4.  Lipoic Acid and Other Antioxidants as Therapies for Multiple Sclerosis.

Authors:  Carin Waslo; Dennis Bourdette; Nora Gray; Kirsten Wright; Rebecca Spain
Journal:  Curr Treat Options Neurol       Date:  2019-05-06       Impact factor: 3.598

5.  Alpha-lipoic acid mitigates toxic-induced demyelination in the corpus callosum by lessening of oxidative stress and stimulation of polydendrocytes proliferation.

Authors:  Nima Sanadgol; Fereshteh Golab; Hassan Askari; Fatemeh Moradi; Marziyeh Ajdary; Mehdi Mehdizadeh
Journal:  Metab Brain Dis       Date:  2017-10-12       Impact factor: 3.584

Review 6.  Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis.

Authors:  Laura E Baldassari; Robert J Fox
Journal:  Drugs       Date:  2018-10       Impact factor: 11.431

7.  Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination.

Authors:  Jeffery D Haines; Olivier Herbin; Belén de la Hera; Oscar G Vidaurre; Gregory A Moy; Qingxiang Sun; Ho Yee Joyce Fung; Stefanie Albrecht; Konstantina Alexandropoulos; Dilara McCauley; Yuh Min Chook; Tanja Kuhlmann; Grahame J Kidd; Sharon Shacham; Patrizia Casaccia
Journal:  Nat Neurosci       Date:  2015-02-23       Impact factor: 24.884

8.  The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis.

Authors:  Petra Hundehege; Manuela Cerina; Susann Eichler; Christian Thomas; Alexander M Herrmann; Kerstin Göbel; Thomas Müntefering; Juncal Fernandez-Orth; Stefanie Bock; Venu Narayanan; Thomas Budde; Erwin-Josef Speckmann; Heinz Wiendl; Anna Schubart; Tobias Ruck; Sven G Meuth
Journal:  Neural Regen Res       Date:  2019-11       Impact factor: 5.135

Review 9.  NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases.

Authors:  Ángel Cores; Marta Piquero; Mercedes Villacampa; Rafael León; J Carlos Menéndez
Journal:  Biomolecules       Date:  2020-06-14

10.  Nociception in a Progressive Multiple Sclerosis Model in Mice Is Dependent on Spinal TRPA1 Channel Activation.

Authors:  Camila Ritter; Diéssica Padilha Dalenogare; Amanda Spring de Almeida; Vitória Loreto Pereira; Gabriele Cheiran Pereira; Maria Fernanda Pessano Fialho; Débora Denardin Lückemeyer; Caren Tatiane Antoniazzi; Sabrina Qader Kudsi; Juliano Ferreira; Sara Marchesan Oliveira; Gabriela Trevisan
Journal:  Mol Neurobiol       Date:  2020-02-24       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.